Literature DB >> 19640996

Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression.

Anne Piantadosi1, Dana Panteleeff, Catherine A Blish, Jared M Baeten, Walter Jaoko, R Scott McClelland, Julie Overbaugh.   

Abstract

The determinants of a broad neutralizing antibody (NAb) response and its effect on human immunodeficiency virus type 1 (HIV-1) disease progression are not well defined, partly because most prior studies of a broad NAb response were cross-sectional. We examined correlates of NAb response breadth among 70 HIV-infected, antiretroviral-naïve Kenyan women from a longitudinal seroincident cohort. NAb response breadth was measured 5 years after infection against five subtype A viruses and one subtype B virus. Greater NAb response breadth was associated with a higher viral load set point and greater HIV-1 env diversity early in infection. However, greater NAb response breadth was not associated with a delayed time to a CD4(+) T-cell count of <200, antiretroviral therapy, or death. Thus, a broad NAb response results from a high level of antigenic stimulation early in infection, which likely accounts for prior observations that greater NAb response breadth is associated with a higher viral load later in infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19640996      PMCID: PMC2748011          DOI: 10.1128/JVI.01149-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

Review 1.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know.

Authors:  Giuseppe Pantaleo; Richard A Koup
Journal:  Nat Med       Date:  2004-08       Impact factor: 53.440

2.  Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition.

Authors:  H L Martin; B A Richardson; P M Nyange; L Lavreys; S L Hillier; B Chohan; K Mandaliya; J O Ndinya-Achola; J Bwayo; J Kreiss
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

3.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

4.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

5.  Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.

Authors:  Y Cao; L Qin; L Zhang; J Safrit; D D Ho
Journal:  N Engl J Med       Date:  1995-01-26       Impact factor: 91.245

6.  HIV-1 evolution in gag and env is highly correlated but exhibits different relationships with viral load and the immune response.

Authors:  Anne Piantadosi; Bhavna Chohan; Dana Panteleeff; Jared M Baeten; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  AIDS       Date:  2009-03-13       Impact factor: 4.177

7.  Injectable contraceptive use and genital ulcer disease during the early phase of HIV-1 infection increase plasma virus load in women.

Authors:  Ludo Lavreys; Jared M Baeten; Joan K Kreiss; Barbra A Richardson; Bhavna H Chohan; Wisal Hassan; Dana D Panteleeff; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Julie Overbaugh
Journal:  J Infect Dis       Date:  2004-01-09       Impact factor: 5.226

8.  A longitudinal assessment of autologous neutralizing antibodies in children perinatally infected with human immunodeficiency virus type 1.

Authors:  Rebeca Geffin; Cecelia Hutto; Carole Andrew; Gwendolyn B Scott
Journal:  Virology       Date:  2003-06-05       Impact factor: 3.616

9.  Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Bhavna H Chohan; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy.

Authors:  Alexandre Harari; Stéphanie Petitpierre; Florence Vallelian; Giuseppe Pantaleo
Journal:  Blood       Date:  2003-09-04       Impact factor: 22.113

View more
  117 in total

1.  Differences in HIV type 1 neutralization breadth in 2 geographically distinct cohorts in Africa.

Authors:  Gama P Bandawe; Penny L Moore; Lise Werner; Elin S Gray; Daniel J Sheward; Maphuti Madiga; Andile Nofemela; Ruwayhida Thebus; Jinny C Marais; Leonard Maboko; Salim S Abdool Karim; Michael Hoelscher; Lynn Morris; Carolyn Williamson
Journal:  J Infect Dis       Date:  2014-11-14       Impact factor: 5.226

2.  Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity.

Authors:  Zelda Euler; Tom L G M van den Kerkhof; Marit J van Gils; Judith A Burger; Diana Edo-Matas; Pham Phung; Terri Wrin; Hanneke Schuitemaker
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

Review 3.  Neutralizing antibodies and control of HIV: moves and countermoves.

Authors:  Ann J Hessell; Nancy L Haigwood
Journal:  Curr HIV/AIDS Rep       Date:  2012-03       Impact factor: 5.071

4.  Infection by discordant strains of HIV-1 markedly enhances the neutralizing antibody response against heterologous virus.

Authors:  Rebecca L R Powell; Thompson Kinge; Phillipe N Nyambi
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

5.  HIV neutralizing antibodies: clinical correlates and implications for vaccines.

Authors:  Nicole A Doria-Rose
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

6.  Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity.

Authors:  Mohammad M Sajadi; Yongjun Guan; Anthony L DeVico; Michael S Seaman; Mian Hossain; George K Lewis; Robert R Redfield
Journal:  J Acquir Immune Defic Syndr       Date:  2011-05-01       Impact factor: 3.731

7.  Determinants of HIV-1 broadly neutralizing antibody induction.

Authors:  Peter Rusert; Roger D Kouyos; Claus Kadelka; Hanna Ebner; Merle Schanz; Michael Huber; Dominique L Braun; Nathanael Hozé; Alexandra Scherrer; Carsten Magnus; Jacqueline Weber; Therese Uhr; Valentina Cippa; Christian W Thorball; Herbert Kuster; Matthias Cavassini; Enos Bernasconi; Matthias Hoffmann; Alexandra Calmy; Manuel Battegay; Andri Rauch; Sabine Yerly; Vincent Aubert; Thomas Klimkait; Jürg Böni; Jacques Fellay; Roland R Regoes; Huldrych F Günthard; Alexandra Trkola
Journal:  Nat Med       Date:  2016-09-26       Impact factor: 53.440

8.  Natural evolution of broadly neutralizing antibodies.

Authors:  Galit Alter; Dan H Barouch
Journal:  Cell       Date:  2015-04-23       Impact factor: 41.582

Review 9.  Strategies to guide the antibody affinity maturation process.

Authors:  Nicole A Doria-Rose; M Gordon Joyce
Journal:  Curr Opin Virol       Date:  2015-04-24       Impact factor: 7.090

10.  Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9.

Authors:  Jean-Philippe Julien; Jeong Hyun Lee; Albert Cupo; Charles D Murin; Ronald Derking; Simon Hoffenberg; Michael J Caulfield; C Richter King; Andre J Marozsan; Per Johan Klasse; Rogier W Sanders; John P Moore; Ian A Wilson; Andrew B Ward
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.